fludarabine has been researched along with deferoxamine in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cory, JG; Montgomery, JA; Sato, A | 1 |
| Andreani, M; Gaziev, J; Lucarelli, G; Polchi, P; Sodani, P | 1 |
| Boyraz, MS; Çağdaş, D; Güçer, Ş; Tezcan, İ; Uçkan Çetinkaya, D; Ünal, Ş | 1 |
3 other study(ies) available for fludarabine and deferoxamine
| Article | Year |
|---|---|
Synergistic inhibition of leukemia L1210 cell growth in vitro by combinations of 2-fluoroadenine nucleosides and hydroxyurea or 2,3-dihydro-1H-pyrazole[2,3-a]imidazole.
Topics: Animals; Cell Survival; Cytidine; Deferoxamine; Deoxyadenosines; Deoxycytidine; Drug Synergism; Hydroxyurea; Kinetics; Leukemia L1210; Mice; Pyrazoles; Vidarabine | 1984 |
Bone marrow transplantation in adults with thalassemia: Treatment and long-term follow-up.
Topics: Adolescent; Adult; Azathioprine; Bone Marrow Transplantation; Busulfan; Chelation Therapy; Clinical Protocols; Combined Modality Therapy; Comorbidity; Deferoxamine; Disease-Free Survival; Erythrocyte Transfusion; Erythropoietin; Female; Follow-Up Studies; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Cell Growth Factors; Hemosiderosis; Humans; Hydroxyurea; Immunosuppressive Agents; Iron Chelating Agents; Life Tables; Liver Cirrhosis; Male; Phlebotomy; Postoperative Complications; Survival Analysis; Thalassemia; Transfusion Reaction; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2005 |
Diagnosis: Melanoderma after Hematopoietic Stem Cell Transplantation.
Topics: Antilymphocyte Serum; Busulfan; Deferoxamine; Diagnosis, Differential; Ecchymosis; Humans; Infant; Iron Overload; Male; Melanosis; Peripheral Blood Stem Cell Transplantation; Severe Combined Immunodeficiency; Transfusion Reaction; Transplantation Conditioning; Vidarabine | 2015 |